Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study
- PDF / 923,538 Bytes
- 9 Pages / 547.087 x 737.008 pts Page_size
- 2 Downloads / 171 Views
(0123456789().,-volV) ( 01234567 89().,-volV)
ORIGINAL PAPER
Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study Ashish Sharma . Francesco Bandello . Anat Loewenstein . Baruch D. Kuppermann . Paolo Lanzetta . Dinah Zur . Assaf Hilely . Matias Iglicki . Daniele Veritti . Angeline Wang . Fernando Miassi . David Bellocq . Leandro Cabral Zacharias . Deepika Makam . Nilesh Kumar . Nikulaa Parachuri . Alan K. Barriera . Rohini Sharma . Hafeez Faridi . Thibaud Mathis . Laurent Kodjikian
Received: 17 September 2019 / Accepted: 21 June 2020 Ó Springer Nature B.V. 2020
Abstract Objective To analyze the role of intravitreal antivascular endothelial growth factor (anti-VEGF) or steroid injection for the management of Irvine Gass syndrome. Methods It is an interventional, retrospective, multicenter study. One hundred and thirty-two injections were given in 79 eyes of 72 patients with Irvine Gass syndrome. Patients were treated with at least one intravitreal injection of either anti-VEGF or steroid.
Outcomes were measured at 12 months (± 1 week). [Ranibizumab (Lucentis; Genentech, South San Francisco, CA) (Razumab; Intas Pharmaceutical Ltd, Ahmedabad, India) Bevacizumab (Avastin; Genentech, South San Francisco, CA) or Aflibercept (Eylea; Regeneron, Tarrytown, NY)] or steroids [Dexamethasone implant (Ozurdex, Allergan Inc, Irvine, CA) or intravitreal triamcinolone)]. Results Intravitreal injections were initiated in (67.6%) of eyes within 14 weeks of diagnosis.
A. Sharma (&) D. Makam N. Kumar N. Parachuri Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, Tamil Nadu 641014, India e-mail: [email protected]
M. Iglicki Private Retina Service, University of Buenos Aires, Buenos Aires, Argentina
F. Bandello Scientific Institute San Raffaele, University Vita-Salute, Milan, Italy A. Loewenstein D. Zur A. Hilely Division of Ophthalmology, Tel Aviv Sourasky Medical Center Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel B. D. Kuppermann A. Wang Gavin Herbert Eye Institute, University of California, Irvine, CA, USA P. Lanzetta D. Veritti Department of Ophthalmology, University of Udine, Udine, Italy
F. Miassi Rosario Retina Clinic, Rosario, Argentina D. Bellocq T. Mathis L. Kodjikian Department of Ophthalmology, Croix-Rousse Hospices Civils de Lyon, University of Lyon, Lyon, France D. Bellocq T. Mathis L. Kodjikian UMR-CNRS 5510 Mate´isVilleurbanne, University of Lyon, Lyon, France L. C. Zacharias A. K. Barriera University of Sa˜o Paulo Medical School, University of Sa˜o Paulo, Sa˜o Paulo, Brazil A. K. Barriera HCLOE Eye Hospital, Sa˜o Paulo, Brazil
123
Int Ophthalmol
Intravitreal dexamethasone implant was used as the initial intravitreal therapy in (73.4%) of eyes. More than fifty percent (54.5%) of the patients were switched from anti-VEGF to Intravitreal dexamethasone implant. Reduction in the mean CMT was 336.7 ± 191.7 and 160.1 ± 153.1 microns in eyes treated within four weeks and more than 14 weeks from diagnosis (p = 0.005
Data Loading...
